A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers
Status:
Recruiting
Trial end date:
2024-07-23
Target enrollment:
Participant gender:
Summary
Primary Objective:
-To determine the antitumor activity of SAR444245 in combination with cemiplimab.
Secondary Objectives:
- To determine the recommended phase 2 dose and to assess the safety profile of SAR444245
when combined with cemiplimab
- To assess other indicators of antitumor activity
- To assess the concentrations of SAR444245 when given in combination with cemiplimab
- To assess the immunogenicity of SAR444245
- To assess active concentrations of cemiplimab when given in combination with SAR444245